FCER1A and anaphylaxis: While previous studies have used SSOs to target the high-affinity IgE receptor FcεRI in MCs (19), the present study employs SSO technology to target the KIT receptor in non-transformed cells, providing yet another tool for the treatment of MC-mediated diseases such as anaphylaxis.